Tactile Systems Technology, Inc. (TCMD)
After hours:
| Previous Close | 14.27 |
| Open | 14.28 |
| Bid | 14.27 x 200 |
| Ask | 17.95 x 200 |
| Day's Range | 13.91 - 14.38 |
| 52 Week Range | 9.69 - 26.11 |
| Volume | |
| Avg. Volume | 293,088 |
| Market Cap | 339.761M |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | 11.63 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Tactile Medical Announces CEO Transition and Preliminary First Quarter 2024 Revenue
CEO Dan Reuvers to retire; Healthcare veteran and board director Sheri Dodd appointed as Chief Executive OfficerPreliminary, unaudited total revenue for first quarter of 2024 expected to be approximately $61 millionManagement to host conference call on May 6, 2024 to discuss first quarter 2024 financial results MINNEAPOLIS, April 23, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for pe
- GlobeNewswire
Tactile Medical to Release First Quarter of Fiscal Year 2024 Financial Results on May 6, 2024
MINNEAPOLIS, April 15, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2024 financial results will be released after the market closes on Monday, May 6, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 6, 2024, to discuss the results of the
- GlobeNewswire
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Outlook
Full Year Revenue Increased 11% Year-Over-Year; Full Year Net Income Increased 260%; Full Year Adjusted EBITDA Increased 62%MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Total revenue increased 5% over pr
